Claims for Patent: 7,229,755

Summary for Patent: 7,229,755

Title:	Method for detection of alterations in the DNA mismatch repair pathway
Abstract:	We have now discovered that eukaryotes, including mammals, have a DNA mismatch repair pathway analogous to the pathway that exists in bacteria. Defects or alterations in this mismatch repair pathway in a mammal, such as a human, will result in the accumulation of unstable repeated DNA sequences. Such a phenotype has a high correlation to disease state in a number of cancers, such as hereditary colon cancers. Accordingly, discovering a defect or alteration in the pathway can be diagnostic of a predisposition to cancer, and prognostic for a particular cancer.
Inventor(s):	Kolodner; Richard D. (Jamaica Plain, MA), Reenan; Robert A. G. (Madison, WI), Fishel; Richard (Penn Valley, PA)
Assignee:	Dana Farber Cancer Institute, Inc. (Boston, MA) University of Vermont and State Agricultural College (Burlington, VT)
Application Number:	08/448,444
Patent Claims:	1. A method of determining whether there is an alteration in a human DNA mismatch repair pathway which comprises: a) isolating a biological specimen from a human; b) testing the specimen for an alteration in a human MSH2 nucleotide sequence or its expression product; and c) comparing the results obtained in step b) with the results obtained from a wild type control. 2. The method of claim 1, wherein the biological specimen is selected from blood, tissue, serum, stool, urine, sputum, cerebrospinal fluid, supernatant from cell lysate and a eukaryotic cell sample. 3. The method of claim 1, wherein an alteration is indicative of a predisposition to malignant growth of cells in the human. 4. The method of claim 1, wherein the biological specimen is selected from a group of blood-related individuals. 5. The method of claim 1, wherein the nucleotide sequence is a gene. 6. The method of claim 1, wherein the expression product is mRNA. 7. The method of claim 1, wherein the specimen is tested for an alteration in a MutS nucleotide sequence or its expression product. 8. The method of claim 1 or claim 3 or claim 7, wherein the specimen is tested for an alteration in the expression product and the expression product is a protein. 9. The method of claim 1, wherein the alteration in the pathway is in the nucleotide sequence of the DNA. 10. The method of claim 9, wherein the alteration in the pathway is detected using a method of DNA amplification. 11. The method of claim 10, wherein the method of DNA amplification detects an alteration in at least one intron or exon. 12. The method of claim 6 or 11, wherein the alteration is detected in a hMSH2 gene using a pair of oligonucleotide primers. 13. A method of determining whether there is an alternation in a human DNA mismatch repair pathway which comprises: (a) isolating a biological specimen from a human; (b) testing the specimen for an alteration in hMSH2 or its expression product; wherein the alteration is detected using a method of DNA amplification wherein the amplification detects an alteration in at least one intron or exon, wherein the alteration is detected using a pair of oligonucleotide primers; and (c) comparing the results obtained in step (b) with the results obtained from a wild type control. 14. The method of claim 13, wherein said oligonucleotide primer of said pair comprising a nucleotide sequence is selected from the group consisting of SEQ ID NOs.:46 65 and 145 154. 15. The method of claim 1 or 8, wherein the alteration in the pathway is detected by measuring the level of gene expression. 16. The method of claim 1, wherein the alteration in the pathway is detected by identifying a mismatch between (1) a mismatch repair pathway gene or its mRNA in said tissue and (2) a nucleic acid probe complementary to a mammalian wild-type mismatch repair gene, when (1) and (2) hybridize to each other to form a duplex. 17. The method of claim 16, wherein the nucleic acid probe is a DNA probe. 18. The method of claim 15, wherein the mismatch is identified by use of enzymatic cleavage. 19. The method of claim 1, wherein the alteration in the DNA mismatch repair pathway is detected by amplification of mismatch repair pathway genes and hybridization of the amplified sequences to nucleic acid probes that are complementary to mutant mismatch repair pathway alleles. 20. A method of diagnosing a tumor associated with defective DNA mismatch repair of a human, comprising: isolating a tissue suspected of being a tumor from said human; detecting an alteration in a human MSH2 DNA mismatch repair pathway gene or its expression product in said tissue wherein said alteration is indicative of a tumor associated with defective DNA mismatch repair. 21. The method of claim 20, wherein the tumor associated with defective DNA mismatch repair is selected from the group of tumors consisting of colorectal, ovary, endometrial, renal, bladder, skin, rectal and small bowel. 22. A method of diagnosis an individual having cancer, comprising, comparing the nucleotide sequence of hMSH2 from a cancer cell from said individual with a non-cancer cell from said individual for the presence of an alteration in the DNA mismatch repair pathway. 23. The method of claim 22, wherein an alteration in the cancer cell and non-cancer cell indicates a germline basis for said cancer. 24. A method of screening for agents affecting the human Mut HLS DNA mismatch repair pathway comprising: a) selecting a first test cell having an alteration in the human Mut HLS DNA mismatch repair pathway; b) selecting a second test cell, wherein said second cell is a corresponding control cell not having the alteration in the human MSH2 DNA mismatch repair pathway; c) contacting said test cells with a selected agent; and d) determining the effect of said agent on DNA mismatch repair in the first and second test cells. 25. A method for isolating a DNA encoding a member of a human MSH2 DNA mismatch repair pathway comprising: a) isolating a biological specimen from a human; b) testing said specimen for an alteration in a human MSH2 DNA mismatch repair pathway gene; and c) isolating DNA comprising said human MSH2 gene. 26. An isolated DNA segment comprising the nucleotide sequence set forth in SEQ ID NO: 8. 27. A vector containing the DNA of claim 26. 28. The vector of claim 27, wherein said vector is a retroviral vector. 29. A host cell transformed with the vector of claim 27 or 28. 30. An isolated and purified antisense DNA segment of the nucleotide sequence set forth in SEQ ID NO: 8 or 45 or fragments thereof, wherein said fragment is at least 30 contiguous nucleotides. 31. A kit for determining an alteration in a member of a human DNA mismatch repair pathway by DNA amplification comprising: a set of DNA oligonucleotide primers, said set allowing synthesis of a DNA encoding hMSH2 or a fragment of at least one exon of hMSH2. 32. The kit of claim 31, wherein said primers are selected from the group of SEQ ID NOs.: 46 65 and 145 154. 33. An isolated and purified molecule comprising at least 30 nucleotides of SEQ ID NO: 8, where said molecule has SEQ ID NO: 6 or 7. 34. The method of claim 1, wherein one detects alterations in DNA mismatch repair pathway nucleotide sequences containing a nucleotide sequence encoding SEQ ID NO: 6 or 7. 35. The method of claim 24, wherein the DNA mismatch repair pathway encodes a protein containing SEQ ID. NO: 6 or 7. 36. The method of claim 21, wherein said endometrial tumor is a uterine tumor. 37. A method of determining whether there is an alteration in a human MSH2 gene which comprises: a) isolating a biological specimen from a human; b) testing the specimen for an alteration in a human MSH2 nucleotide sequence or its expression product; and c) comparing the results obtained in step b) with the results obtained from a wild type control. 38. The method of claim 8, wherein the specimen is tested for an alteration in the protein by an immunohistochemical assay. 39. The method of claim 8, wherein the specimen is tested for an alteration in the protein by an antibody specific for human MSH2. 40. The method of claim 39, wherein the antibody specific for human MSH2 is generated by using an immunogenic fragment of SEQ ID NO: 16. 41. The method of claim 39, wherein the antibody specific for human MSH2 binds to the carboxy terminus of the protein. 42. An antibody specific for the human MSH2 protein. 43. A protein fragment generated by PCR amplification using a primer pair selected from SEQ ID NO: 8 that generates at least an exon of the MSH2 genomic sequence. 44. A protein fragment generated using a primer pair, wherein the primer pair is selected from the group consisting of SEQ ID Nos: 17/18, 17/23, 25/26, 29/30, 81/32, 33/34, 35/36, 37/38 and 39/40. 45. The protein fragment of claim 43, wherein said protein fragment is an immunogen. 46. A protein fragment encoded by the DNA segment of claim 26. 47. The method of claim 1, wherein the specimen is tested for an alteration in a hMSH2 nucleotide sequence or its expression product. 48. A kit for determining an alteration in a member of a DNA mismatch repair pathway using an antibody that specifically binds to human MSH2. 49. The kit of claim 7, wherein the alteration is determined by using an antibody.

Details for Patent 7,229,755

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2024-06-12
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2024-06-12
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2024-06-12